千金药业(600479.SH)：上交所并购重组审核委员会于8月18日召开审议会议

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) announced that the Shanghai Stock Exchange's M&A Review Committee will hold a meeting on August 18, 2025, to review the company's application for the current transaction [1] Group 1 - The M&A Review Committee of the Shanghai Stock Exchange is scheduled to convene for its 12th review meeting of 2025 [1] - The meeting will specifically focus on the review of Qianjin Pharmaceutical's transaction application [1]